Vitamin D Supplementation is Associated with Increased Glutathione Peroxidase-1 Levels in Arab Adults with Prediabetes

Mohammed Ghouse Ahmed Ansari 1, Shaun Sabico 1, Mario Clerici 2,3, Malak Nawaz Khan Khattak 1, Kaiser Wani 1, Sara Al-Musharaf 1, Osama Emam Amer 1, Majed S. Alokail 1 and Nasser M. Al-Daghri 1,*

1 Chair for Biomarkers of Chronic Diseases, Riyadh Biochemistry Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia; mansari@ksu.edu.sa (M.G.A.A.); ssabico@ksu.edu.sa (S.S.); mkhattak@ksu.edu.sa (M.N.K.K.); kwani@ksu.edu.sa (K.W.); oamer1@ksu.edu.sa (O.E.A.); malokail@ksu.edu.sa (M.S.A.)
2 Department of Physiopathology and Transplantation, University of Milan, via Francesco Sforza, 35, 2022 Milan, Italy; mario.clerici@unimi.it
3 IRCCS Fondazione Don Carlo Gnocchi, 20148 Milan, Italy
4 Department of Community Health, College of Applied Medical Sciences, King Saud University, Riyadh 11451, Saudi Arabia; salmosharruf@ksu.edu.sa

* Correspondence: ndaghri@ksu.edu.sa; Tel.: +966-11-467-5939

Received: 24 December 2019; Accepted: 26 January 2020; Published: 29 January 2020

Abstract: Vitamin D supplementation may be used to lower oxidative stress. This interventional study aimed to investigate the effects of vitamin D supplementation on glutathione peroxidase 1 (GPx1) levels and other parameters in Arab adults with prediabetes. A total of 203 Saudi adults with prediabetes and vitamin D deficiency [intervention group, \( N = 146 \) (53 males and 93 females); control group, \( N = 57 \) (25 males and 32 females)] were included in this non-randomized, six-month intervention study. The intervention group received 50,000 international units (IU) cholecalciferol tablets once a week for two months, then twice a month for the next two months, followed by 1000 IU daily for the last two months. The control group received no supplementation. Serum 25(OH)D, lipid profile, glucose, C-reactive protein (CRP) and GPx1 were measured at baseline and after six months. Post-intervention, GPx1 concentrations increased significantly in the intervention group \([17.3 (11.5–59.0) \text{ vs } 26.7 (11.4–59.9)] \ p < 0.01\) while no changes were observed in the control group \( (p = 0.15)\). This significant increase in 25(OH)D and GPx1 levels persisted after adjusting for age and BMI. Stratification according to sex revealed that this favourable increase in GPx1 was true only for males \( (p = 0.002)\). In all groups, baseline GPx1 was inversely correlated with low density lipoprotein (LDL)-cholesterol \( (r = -0.26, p < 0.01)\) and body mass index (BMI) \( (r = -0.20, p < 0.05)\), while positively correlated with age \( (r = 0.18, p < 0.05)\) and systolic blood pressure \( (r = 0.19, p < 0.05)\). In conclusion, vitamin D supplementation favourably enhanced GPx1 levels in adult Arabs with prediabetes, particularly in males.

Keywords: oxidative stress; glutathione peroxidase; vitamin D supplementation

1. Introduction

Diabetes mellitus (DM)—a metabolic disorder characterized by insulin resistance and pancreatic \( \beta \)-cell damage—is one of the most common diseases in modern times, affecting around 451 million people globally and is expected to reach 693 million by 2045 [1]. In parallel, the pandemic of vitamin D deficiency has become a global health concern affecting people of all ages [2]. Saudi Arabia alone...
has an estimated population of 7 million living with DM in addition to 3 million with prediabetes, with an overall prevalence of vitamin D deficiency (<50 nmol/L) at 81.0% (confidence interval 95% 68.0–90.0) from 2011 to 2016 [3,4]. Sedentary lifestyle, environmental factors and genetic predisposition are considered major factors in the development of DM in the region [5–10].

Chronic hyperglycemia in DM induces excess production of free radicals [11]. Elevated oxidative stress caused by reactive oxygen species (ROS) plays a causal role in the pathogenesis of DM and related complications [12,13] via increased insulin resistance or impaired insulin secretion [14,15]. Oxidative stress can be defined as the imbalance between production and degradation of ROS [16]. Several studies have shown that it acts as a triggering factor for an array of human disorders including DM [13], cardiovascular disorders [17,18], cancers [19,20], neurodegenerative disorders [21] and autoimmune diseases [22].

Traditionally, 25-hydroxy vitamin D (25(OH)D) was considered essential in calcium homeostasis for optimal skeletal health, but recent scientific advances revealed its extraskeletal functions and associations with various clinical conditions [23–25]. Vitamin D deficiency has been considered a risk factor in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) [26–28]. On the other hand, glutathione peroxidase (GPx) family plays a crucial role in the enzymatic antioxidant defense system. GPx1 is a ubiquitously expressed abundant isoform of the GPx family and acts as a protagonist in detoxifying harmful lipid-peroxides by converting hydrogen peroxide to lipid alcohol and water respectively, using glutathione as an electron donor [29,30].

Several lines of evidence highlight the protective role of GPx1 in patients with DM [31–33]. Similarly, some studies have suggested that vitamin D may have antioxidant properties [34]. Evidence from our previous study suggested that vitamin D supplementation maybe a promising adjuvant therapy for T2DM patients [35]. However, we found a paucity of vitamin D interventional studies with regards to antioxidant activities. We hypothesize that improving vitamin D status may favourably regulate GPx1 activity and may, therefore, delay the progression of individuals with prediabetes to T2DM. Hence the present study aimed to determine the effects of vitamin D supplementation on GPx1 levels in Saudi adults with prediabetes.

2. Materials and Methods

2.1. Participants

In this 6-month interventional study, a total of 257 adult Saudis aged 30–60 years, with vitamin D deficiency [25(OH)D < 50 nmol/L], were randomly selected from the Vitamin D Database of the Chair for Biomarkers of Chronic Diseases (CBCD), King Saud University (KSU), Riyadh, Kingdom of Saudi Arabia (KSA) and were assigned in the intervention group. A separate group of 57 adult Saudis (age- and BMI-matched) with vitamin D deficiency were also selected from the database. Briefly, this database was based on a capital-wide, multi-centre observational study done in primary health care centres (PHCCs) in Riyadh, Saudi Arabia, [36,37]. Written informed consents were obtained prior to inclusion in the study. Ethical approval was obtained from the Institutional Review Board (IRB) of King Saud Medical City (E-15-1667), Riyadh, Saudi Arabia. Participants answered a questionnaire that included demographic information, present and past medical history.

Exclusion Criteria

Participants with chronic clinical conditions (T2DM, cardiovascular diseases (CVD), cancer, gastrointestinal disease, osteopenia/osteoporosis, thyroid, liver and renal dysfunction), on any medication or vitamin D supplementation and whose baseline 25(OH)D levels were above 50 nmol/L were excluded from the study. A total of 84 participants were excluded because of the presence of the mentioned conditions for exclusion in their data file and another 27 participants were excluded for having baseline 25(OH)D levels above 50 nmol/L. All excluded participants (N = 111) were from the
intervention group. Hence, 230 participants [intervention group, $N = 146$ (53 males and 93 females); control group, $N = 57$ (25 males and 32 females)] qualified for this interventional study (Figure 1).

**Figure 1.** Modified CONSORT diagram for non-randomized design.

### 2.2. Anthropometry and Biochemical Assessments

Anthropometric variables (waist circumference, hip circumference, waist to hip ratio (WHR), body mass index (BMI), systolic and diastolic blood pressure) and biochemical parameter ($25\text{[OH]}\text{D}$, fasting glucose and lipid profile) measurements were done at baseline and post-intervention by following the procedure and protocols, as described in our previous study [38].
Serum levels of GPx1 and CRP were measured using ELISA kits (Abcam®, Cambridge, UK and R&D SYSTEMS®, Minneapolis, MN, USA, respectively) following manufacturers’ instructions. The variations in intra-assay and inter-assay as obtained were 4.17% and 9.8% for GPx1 and 5.5–6.5% for CRP respectively. To minimize inter-assay variability, all samples were analyzed simultaneously and the actual variations were well within the inter- and intra-assay ranges.

2.3. Intervention

The intervention group received oral 50,000IU cholecalciferol tablets (VitaD50000) (Synergy pharma, Dubai, UAE) given once a week for the first two months then twice a month for the next two months, followed by 1000 IU (VitaD1000) (Synergy pharma, Dubai, UAE) daily for the last two months. Participants were regularly encouraged through Short Message Service (SMS) to take the recommended vitamin D dose. To ensure compliance, participants were requested to return unused tablets every follow-up visit (if any) before a refill of supplements was given. Dosages were based on the national recommendations for the management of vitamin D deficiency [39]. The control group did not receive any vitamin D supplementation but were given advice on how to increase vitamin D status non-pharmacologically (increased sunlight exposure and dietary intake of vitamin D-rich foods).

2.4. Statistical Analysis

Data were analyzed using SPSS version 21.0, IBM (Armonk, NY, USA). Mean ± standard deviation (SD) were used to present normal variables, while the median (1st and 3rd) percentiles were used for non-normal variables. All categorical variables were presented in percentages (%). Kolmogorov–Smirnov test was applied to check the normality. Non-normal variables were transformed prior to parametric testing. Paired T-Test and Wilcoxon tests were used to check the mean and median differences (changes) for Gaussian variables and non-Gaussian variables, respectively. Repeated measures ANOVA, was used to determine group and interaction effects. Pearson’s correlation analysis was done to determine the correlation between GPx1 and select variables. A p-value <0.05 was considered statistically significant.

3. Results

A total of 203 (78 males and 125 females) vitamin D deficient Saudi adults participated in this six-month interventional study. Baseline comparisons of groups are presented in supplementary Table S1. There were no significant differences in all the parameters assessed in both groups at baseline. Table 1 shows the clinical characteristics of groups at pre- and post-intervention. Within-group comparisons in the intervention group showed a significant increase in glucose (p = 0.04), 25(OH)D (p < 0.01) and GPx1 (p < 0.01) overtime. In the control group, there was a significant increase in total cholesterol (p = 0.03) and HDL-cholesterol (p < 0.001) with a subsequent decrease in 25(OH)D (p = 0.01). Between-group comparisons revealed a clinically significant improvement in 25(OH)D (p < 0.001) and GPx1 (p < 0.01) in favour of the intervention group. The rest of the between-group comparisons were not significant (Table 1).

Table 2. Shows the within- and between-group comparisons of both groups according to sex. As expected, serum 25(OH)D significantly increased over time and between-groups in favour of the intervention group in both sexes. This clinically significant increase persisted even after adjusting for age and BMI (p < 0.001). With regard to GPx1 however, the significant increase over time was observed in male subjects of the intervention group and this effect remained significant in between-group comparisons even after adjusting for age and BMI (p = 0.023).
Table 1. Clinical Characteristics of Groups Before and After 6 Months of Intervention.

| Parameters                          | Intervention Before | Intervention After | Change (1st–3rd) percentile | p-Value | Control Before | Control After | Change (1st–3rd) percentile | p-Value |
|-------------------------------------|---------------------|--------------------|-----------------------------|---------|---------------|---------------|-----------------------------|---------|
| N (M/F)                             | 146 (53/93)         | 57 (25/32)         |                             |         |
| Total Cholesterol (mmol/L)          | 5.1 ± 1.2           | 5.12 ± 1.2         | -0.02 (−0.2–0.16)           | 0.52    | 5.07 ± 1.0    | 5.51 ± 1.2    | 0.44 (0.13–0.75)            | 0.03    |
| HDL-Cholesterol (mmol/L)            | 1.0 ± 0.4           | 1.15 ± 0.40        | 0.11 (0.02–0.19)            | 0.14    | 1.05 ± 0.5    | 1.30 ± 0.4    | 0.22 (0.08–0.37)            | <0.001  |
| LDL-Cholesterol (mmol/L)            | 3.2 ± 0.9           | 3.14 ± 0.9         | -0.01 (−0.3–0.06)           | 0.12    | 3.30 ± 0.8    | 3.44 ± 0.9    | 0.14 (−0.14–0.41)           | 0.65    |
| Triglycerides (mmol/L) #            | 1.5 (1.0–2.1)       | 1.49 (1.1–1.9)     | 0.01 (−0.4–0.4)             | 0.56    | 1.18 (0.8–1.8) | 1.51 (0.9–2.3) | 0.24 (−0.26–0.9)           | 0.12    |
| Glucose (mmol/L)                    | 5.5 ± 0.9           | 5.6 ± 0.9          | 0.07 (−0.1–0.23)            | 0.04    | 5.35 ± 0.10   | 5.48 ± 0.8    | 0.13 (−0.17–0.44)           | 0.98    |
| CRP (µg/mL)#                        | 20.6 (4.5–49.5)     | 39.9 (14.9–75.9)   | 0.27 (−10.5–4.5)            | 0.39    | 17.7 (5.2–40) | 34.7 (8.0–80.4) | 0.13 (−20.1–17.7)           | 0.22    |
| 25(OH)D (nmol/L)                    | 32.5 ± 11.6         | 66.2 ± 18.01       | 33.7 (30.6–36.8)            | <0.01   | 31.9 ± 15.3   | 29.10 ± 12.4  | −2.8 (−6.2–0.8)            | 0.01    |
| GPx1 (ng/mL)                        | 17.3 (11.5–59.0)    | 26.7 (11.4–59.9)   | 7.5 (–1.7–8.2)              | <0.01   | 14.6 (7.6–56) | 16.3 (8.5–66.3) | 1.9 (−4.5–6)              | 0.15    |

Table 2. 25(OH) D and GPX-1 at Baseline and After 6 Months of Intervention.

| Parameter | Males | Females | Group Effect | Group Effect (Adjusted for age & BMI) |
|-----------|-------|---------|--------------|--------------------------------------|
|           | Intervention (N = 53) | Control (N = 25) | Intervention (N = 93) | Control (N = 32) |
| 25 (OH) D (nmol/L) | 34.9 ± 10.8 | 38.6 ± 13.7 | 30.9 ± 14.5 | 29.2 ± 16.2 | <0.001 | <0.001 |
| 6 months | 60.1 ± 20.2 | 32.8 ± 9.5 | 54.3 ± 24.5 | 27.4 ± 12.9 |
| Change (1st–3rd) percentile | 26.0 (19.8–32.2) | -2.5 (22.4–7.3) | 21.1 (15.1–26.1) | -1.2 (10.9–7.9) |
| Time effect | <0.001 | <0.001 | <0.001 | <0.001 |
| Time effect (Adjusted) | <0.001 | <0.001 | <0.001 | <0.001 |

GPx1 (ng/mL)

Baseline | 24.6 (14–140) | 16.6 (13.4–23.5) | 14.9 (11.1–41.6) | 11.1 (9.8–13.1) | < 0.001 | < 0.023 |
| 6 months | 30.1 (12–140) | 18.6 (10.2–27.2) | 16.1 (10.1–44.5) | 11.5 (11.5–14.1) |
| Change (1st–3rd) percentile | 8.9 (2.9–14.9) | 2.04 (−5.7–6.4) | 6.9 (2.7–11.1) | 0.16 (−1.6–2.8) |
| Time effect | 0.004 | 0.06 | 0.002 | 0.57 |
| Time effect (Adjusted) | 0.002 | 0.002 | 0.002 | 0.002 |

Note: Data presented as mean ± standard deviation, Median (1st and 75th) percentiles and mean and median change (95% CI); Adjusted for age and BMI; significant at p < 0.05.
Table 3 shows the bivariate correlation coefficients of GPx1 and other parameters for all participants at different time points according to groups. Overall and at baseline, GPx1 was inversely correlated with LDL-cholesterol \((r = -0.26, p < 0.01)\) and BMI \((r = -0.20, p < 0.05)\), while positively correlated with age \((r = 0.18, p < 0.05)\) and systolic BP \((r = 0.19, p < 0.05)\). In the intervention group, baseline GPx1 was inversely correlated with LDL-cholesterol \((r = -0.22, p < 0.05)\) and total cholesterol \((r = -0.19, p < 0.05)\) as well as positively correlated with WHR \((r = 0.25, p < 0.01)\) systolic BP \((r = 0.21, p < 0.05)\) and diastolic BP \((r = 0.26, p < 0.01)\). In the control group, baseline GPx1 levels were positively correlated with triglycerides \((r = 0.33, p < 0.05)\). Lastly, Figure 2 shows the significant positive association between post-intervention levels of 25(OH)D and GPx1 in the intervention group \((R = 0.29; p = 0.002)\). This post-intervention association was not observed in controls.

**Table 3. Baseline GPx1 Associations in All Groups.**

| Parameters                        | All | Intervention | Control |
|-----------------------------------|-----|--------------|---------|
| Age (year)                        | 0.18* | 0.19         | 0.05    |
| Body Mass Index (BMI) (kg/m²)     | -0.20* | -0.17        | 0.21    |
| Waist Hip Ratio (WHR)             | 0.20 | 0.25**       | 0.25    |
| Systolic BP (mmHg)                | 0.19* | 0.21*        | 0.20    |
| Diastolic BP (mmHg)               | 0.16 | 0.26**       | 0.14    |
| Total Cholesterol (mmol/L)        | -0.11 | -0.19*       | -0.04   |
| HDL-Cholesterol (mmol/L)          | 0.12 | 0.15         | 0.18    |
| LDL-Cholesterol (mmol/L)          | -0.26** | -0.22*       | -0.20   |
| Triglycerides (mmol/L) #          | 0.10 | 0.01         | 0.33*   |
| Glucose (mmol/L)                  | 0.16 | 0.04         | 0.16    |
| 25(OH)D (nmol/L)                  | 0.06 | 0.03         | 0.20    |
| CRP (µg/mL) #                     | -0.10 | -0.08        | 0.10    |

*Note:* Data presented as a coefficient (R); # denotes Non-Gaussian; * denotes significance at 0.05 level; ** denotes significance at 0.01 level.

**Figure 2.** Relationship between Log 25(OH) D and GPx1 in all participants (Post-intervention).

4. Discussion

This interventional study revealed a clinically significant improvement in the vitamin D status and GPx1 levels after six months of vitamin D supplementation in favour of the intervention group. HDL-cholesterol increased significantly among female participants of the control group while fasting blood glucose modestly increased in male participants of the intervention group. These changes
were not clinically significant in between-group comparisons. In all participants, GPx1 levels were significantly and inversely correlated with LDL-cholesterol in both time points and positively with 25(OH)D only at post-intervention. Finally, the significant improvement in GPx1 levels post-vitamin D supplementation were observed only in males.

T2DM is characterized by insulin resistance and/or insulin secretory dysfunction which can be influenced by vitamin D status. In the present study, serum 25(OH)D levels significantly improved in the intervention group post-vitamin D supplementation and these beneficial changes may help in improving glycemic control [35,40,41]. Other studies however revealed neither improvement in glycemic status [42] nor decreased diabetes risk in response to vitamin D supplementation [43].

At baseline, low GPx1 levels were observed in all participants. Similar results were reported in T2DM patients [44,45] and in the Athero Gene study of CVD patients, suggesting that patients with low erythrocyte GPx1 activities had an increased incidence of recurrent events [46,47]. Elevated ROS act as second messengers which signal inflammasome activation [48]. This may be reflected in our results with females, where expression of the inflammatory protein CRP was modestly reduced post-intervention.

In the present study, the significant positive associations of GPx1 to known cardiometabolic factors such as age, BMI and blood pressure, as well as the inverse association with LDL-cholesterol, highlight the known protective role of GPx1 in decreasing the chronic sub-inflammatory status observed in diseases such as T2DM [31–33]. Our findings showed a significant positive correlation between GPx1 levels with 25(OH)D levels, and may, therefore, reduce oxidative stress in patients with prediabetes. These findings are in line with a recent study on decreased oxidative stress in paraspinal skeletal muscles of low back pain patients who received vitamin D supplementation [49]. Interestingly, only LDL-cholesterol was associated with GPx1 in the present study. A similar study, however, done among overweight and obese populations of central Mexico revealed significant associations between HDL and triglycerides with GPx [50]. These differences may indicate that GPx is highly variable in human populations having different health conditions as well as ethnicity [51].

Lastly, the favorable increase in GPx1 observed only in males post-vitamin D intervention highlight the sex-specific extra-skeletal effects of vitamin D correction. Our previous observation involving more than 3000 Saudi adolescents and adults revealed that vitamin D deficiency and its association with cardiometabolic risk factors were mostly limited to males. This led us to believe that vitamin D correction may prove more beneficial to men than women, at least in terms of extraskeletal benefits [52]. One explanation that we have also recently documented at the proteomic level is that the conversion of 25(OH)D to its active form, 1,25(OH)D$_2$ is higher in men than women, and this can be linked to sex hormone metabolism [53].

The authors acknowledge certain limitations. Even though baseline characteristics between control and intervention group were not significant, randomization was not done in the present study and as such, there is a chance of bias in reported changes, post-intervention. Other antioxidant markers were unfortunately not included in the present study and this could have enhanced, if not supplemented our hypothesis that vitamin D has antioxidant properties. Nevertheless, this study is the first of its kind to explain the effects of vitamin D supplementation on GPx1 levels.

5. Conclusions

Vitamin D supplementation modulates GPx1 levels that can favourably benefit vitamin D deficient patients with prediabetes, particularly males. The present study should be further explored to see how vitamin D supplementation stimulates the antioxidant system by investigating other antioxidant markers, including the trace minerals.

Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3921/9/2/118/s1, Table S1: Baseline Characteristics of Intervention and Control Groups.

Author Contributions: Conceptualization, M.G.A.A. and N.M.A.-D.; methodology, K.W.; formal analysis, M.N.K.K.; investigation, M.G.A.A., S.A.-M., O.E.A.; resources, N.M.A.-D. and M.S.A.; data curation, S.S. and M.N.K.K; writing—original draft preparation, M.G.A.A.; writing—review and editing S.S., M.C., M.N.K.K., K.W.,
S.A.-M., O.E.A., M.S.A., N.M.A.-D.; supervision, M.C.; project administration, N.M.A.-D. and M.S.A.; funding acquisition, M.S.A. All authors have read and agreed to the published version of the manuscript.

**Funding:** The authors extend their appreciation to the International Scientific Partnership program at King Saud University, Riyadh, KSA for funding this research through ISPP-118.

**Acknowledgments:** The authors are thankful to Synergy Pharma, Dubai, UAE for the provision of vitamin D supplements and to Syed Danish Hussain for the statistical analysis.

**Conflicts of Interest:** The authors declare no conflicts of interest.

**References**

1. Cho, N.; Shaw, J.; Karuranga, S.; Huang, Y.; da Rocha Fernandes, J.; Ohlrogge, A.; Malanda, B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res. Clin. Pr.* 2018, 138, 271–281. [CrossRef]

2. Al-Daghri, N.M.; Ansari, M.G.A.; Sabico, S.; Al-Saleh, Y.; Aljohani, N.J.; Alfawaz, H.; Alharbi, M.; Al-Othman, A.M.; Alokail, M.S.; Wimalawansa, S.J. Efficacy of different modes of vitamin D supplementation strategies in Saudi adolescents. *J. Steroid Biochem. Mol. Biol.* 2018, 180, 23–28. [CrossRef]

3. Alwin Robert, A.; Abdulaziz Al Dawish, M.; Braham, R.; Ali Musallam, M.; Abdullah Al Hayek, A.; Hazza Al Kahtany, N. Type 2 diabetes mellitus in Saudi Arabia: Major challenges and possible solutions. *Curr. Diabetes Rev.* 2017, 13, 59–64. [CrossRef] [PubMed]

4. Al-Daghri, N.M. Vitamin D in Saudi Arabia: Prevalence, distribution and disease associations. *J. Steroid Biochem. Mol. Biol.* 2018, 175, 102–107. [CrossRef] [PubMed]

5. Zimmet, P.; Lecture, K.W. Challenges in diabetes epidemiology form West to the rest. *Diabetes Care* 1992, 15, 232–252. [CrossRef] [PubMed]

6. Zimmet, P.; Alberti, K.; Shaw, J. Global and societal implications of the diabetes epidemic. *Nature* 2001, 414, 782. [CrossRef]

7. Perez-Bravo, F.; Carrasco, E.; Gutierrez-Lopez, M.; Martinez, M.; Lopez, G.; de los Rios, M.G. Genetic predisposition and environmental factors leading to the development of insulin-dependent diabetes mellitus in Chilean children. *J. Mol. Med.* 1996, 74, 105–109. [CrossRef]

8. Al-Daghri, N.M.; Al-Attas, O.; Alokail, M.S.; Alkhafry, K.M.; Draz, H.M.; Agliardi, C.; Mohammed, A.K.; Guerini, F.R.; Clerici, M. Vitamin D receptor gene polymorphisms and HLA DRB1* 04 cosegregation in Saudi type 2 diabetes patients. *J. Immunol.* 2012, 188, 1325–1332. [CrossRef]

9. Raciti, G.A.; Longo, M.; Parrillo, L.; Ciccarelli, M.; Mirra, P.; Ungaro, P.; Formisano, P.; Miele, C.; Béguinot, F. Understanding type 2 diabetes: From genetics to epigenetics. *Acta Diabetol.* 2015, 52, 821–827. [CrossRef]

10. Al-Daghri, N.M.; Al-Attas, O.S.; Alkhafry, K.M.; Khan, N.; Mohammed, A.K.; Vinodson, B.; Ansari, M.G.A.; Alenad, A.; Alojail, M.S. Association of VDR-gene variants with factors related to the metabolic syndrome, type 2 diabetes and vitamin D deficiency. *Gene* 2014, 542, 129–133. [CrossRef]

11. Lee, W.C.; Mokhtar, S.S.; Munisamy, S.; Yahaya, S.; Rasool, A.A.; Vitamin D status and oxidative stress in diabetes mellitus. *Cell Mol. Biol (Noisy-Le-Grand)* 2018, 64, 60–69. [CrossRef]

12. Asmat, U.; Abad, K.; Ismail, K. Diabetes mellitus and oxidative stress—a concise review. *Saudi Pharm. J.* 2016, 24, 547–553. [CrossRef] [PubMed]

13. Giacco, F.; Brownlee, M. Oxidative stress and diabetic complications. *Circ. Res.* 2010, 107, 1058–1070. [CrossRef] [PubMed]

14. Katsuki, A.; Sumida, Y.; Urakawa, H.; Gabazza, E.C.; Murashima, S.; Nakatani, K.; Yano, Y.; Adachi, Y. Increased oxidative stress is associated with serum levels of triglyceride, insulin resistance, and hyperinsulinemia in Japanese metabolically obese, normal-weight men. *Diabetes Care* 2004, 27, 631–632. [CrossRef]

15. Ceriello, A. Oxidative stress and glycemic regulation. *Metab. Clin. Exp.* 2000, 49, 27–29. [CrossRef]

16. Durackova, Z. Some current insights into oxidative stress. *Physiol. Res.* 2010, 59, 459.

17. Brunelli, E.; La Russa, D.; Pellegrino, D. Impaired Oxidative Status Is Strongly Associated with Cardiovascular Risk Factors. *Oxid. Med. Cell Longev.* 2017. [CrossRef]

18. Ndrepepa, G. Myeloperoxidase - A bridge linking inflammation and oxidative stress with cardiovascular disease. *Clin. Chim. Acta* 2019, 493, 36–51. [CrossRef]

19. Lau, A.T.; Wang, Y.; Chiu, J.F. Reactive oxygen species: Current knowledge and applications in cancer research and therapeutic. *J. Cell. Biochem.* 2008, 104, 657–667. [CrossRef]
20. Brown, N.S.; Bicknell, R. Hypoxia and oxidative stress in breast cancer. Oxidative stress—its effects on the growth, metastatic potential and response to therapy of breast cancer. *Breast Cancer Res.* 2001, 3, 323. [CrossRef]

21. Bolaños, J.P.; Moro, M.A.; Lizzasain, I.; Almeida, A. Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: Therapeutic implications. *Adv. Drug Deliv. Rev.* 2009, 61, 1299–1315. [CrossRef] [PubMed]

22. Gelderman, K.A.; Hultqvist, M.; Olsson, L.M.; Bauer, K.; Pizzolla, A.; Olofsson, P.; Holmdahl, R. Rheumatoid arthritis: The role of reactive oxygen species in disease development and therapeutic strategies. *Antioxid. Redox Signal.* 2007, 9, 1541–1568. [CrossRef] [PubMed]

23. Tohari, A.M.; Alhasani, R.H.; Biswas, L.; Patnaik, S.R.; Reilly, J.; Zeng, Z.; Xu, X. Vitamin D Attenuates Oxidative Damage and Inflammation in Retinal Pigment Epithelial Cells. *Antioxidant* 2019, 8, 341. [CrossRef]

24. Al-Daghri, N.M.; Alkharfy, K.M.; Al-Othman, A.; El-Kholie, E.; Moharram, O.; Alokail, M.S.; Al-Saleh, Y.; Alenad, A.; Al-Saleh, Y.; et al. Efficacy of vitamin D supplementation according to vitamin D-binding protein polymorphisms. *Nutrition* 2019, 63–64, 148–154. [CrossRef] [PubMed]

25. Brett, N.R.; Lavery, P.; Agellon, S.; Vanstone, C.A.; Goruk, S.; Field, C.J.; Weiler, H.A. Vitamin D Status and Immune Health Outcomes in a Cross-Sectional Study and a Randomized Trial of Healthy Young Children. *Nutrition* 2018, 10, 680. [CrossRef] [PubMed]

26. Alhumaidi, M.; Adnan, A.; Dewish, M. Vitamin d deficiency in patients with type-2 diabetes mellitus in southern region of saudi arabia. *Maedica* 2013, 8, 231.

27. Svören, B.M.; Volkening, L.K.; Wood, J.R.; Laffel, L.M. Significant vitamin D deficiency in youth with type 1 diabetes mellitus. *J. Pediatrics* 2009, 154, 132–134. [CrossRef]

28. Di Cesar, D.J.; Ploutz-Snyder, R.; Weinstock, R.S.; Moses, A.M. Vitamin D deficiency is more common in type 2 than in type 1 diabetes. *Diabetes Care* 2006, 29, 174. [CrossRef]

29. Teng, T.; Prior, S.; Li, K.; Ireland, H.; Bain, S.; Hurel, S.; Cooper, J.; Humphries, S.; Stephens, J. Association between the rs1050450 glutathione peroxidase-1 (C > T) gene variant and peripheral neuropathy in two independent samples of subjects with diabetes mellitus. *Nutr. Metab. Cardiovasc. Dis.* 2012, 22, 417–425. [CrossRef]

30. Matés, J.M.; Pérez-Gómez, C.; De Castro, I.N. Antioxidant enzymes and human diseases. *Clin. Biochem.* 1999, 32, 595–603. [CrossRef]

31. Dominguez, C.; Ruiz, E.; Gussinye, M.; Carrascosa, A. Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. *Diabetes Care* 1998, 21, 1736–1742. [CrossRef] [PubMed]

32. Bhattia, S.; Shankla, R.; Madhu, S.V.; Gambhir, J.K.; Prabhu, K.M. Antioxidant status, lipid peroxidation and nitric oxide end products in patients of type 2 diabetes mellitus with nephropathy. *Clin. Biochem.* 2003, 36, 557–562. [CrossRef]

33. Ndahimana, J.; Dorsey, H.; Vertongen, F. Erythrocyte and plasma antioxidant activity in diabetes mellitus type 1. *Presse Med.* 1996, 25, 188–192. [PubMed]

34. Mukhopadhyay, S.; Singh, M.; Chatterjee, M. Vitamin D3 as a modulator of cellular antioxidant defence in murine lymphoma. *Nutr. Res.* 2000, 20, 91–102. [CrossRef]

35. Al-Daghri, N.M.; Alkhafry, K.M.; Al-Othman, A.; Al-Kholie, E.; Moharram, O.; Alokail, M.S.; Al-Saleh, Y.; Sabico, S.; Kumar, S.; Chrousos, G.P. Vitamin D supplementation as an adjuvant therapy for patients with T2DM: An 18-month prospective interventional study. *Cardiovasc. Diabetol.* 2012, 11, 85. [CrossRef] [PubMed]

36. Al-Daghri, N.M.; Wani, K.; Sabico, S.; Garbis, S.D.; Chrousos, G.P.; Amer, O.E.; Ansari, M.G.A.; Al-Saleh, Y.; Aljohani, N.J.; Al-Attas, O.S. IGF and IGFBP as an index for discrimination between vitamin D supplementation responders and nonresponders in overweight Saudi subjects. *Medicine* 2018, 97. [CrossRef]
Antioxidants 2020, 9, 118 10 of 10

39. Al-Daghri, N.M.; Al-Saleh, Y.; Aljohani, N.; Suliman, R.; Al-Othman, A.M.; Alfawaz, H.; Fouda, M.; Al-Amri, F.; Shahrani, A.; Alharbi, M.; et al. Vitamin D status correction in Saudi Arabia: An experts’ consensus under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO). Arch. Osteoporos 2017, 12, 1. [CrossRef]

40. Kostoglou-Athanassiou, I.; Athanassiou, P.; Gkountouvas, A.; Kaldrymides, P. Vitamin D and glycemic control in diabetes mellitus type 2. Adv. Endocrinol. Metab. 2013, 4, 122–128. [CrossRef]

41. Mitri, J.; Dawson-Hughes, B.; Hu, F.B.; Pittas, A.G. Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: The Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. Am. J. Clin. Nutr 2011, 94, 486–494. [CrossRef]

42. Moreira-Lucas, T.S.; Duncan, A.M.; Rabasa-Lhoret, R.; Veith, R.; Gibbs, A.L.; Badawi, A.; Wolever, T.M.S. Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes (EVIDENCE): A double-blind, randomized, placebo-controlled clinical trial. Diabetes Obes. Metab. 2017, 19, 133–141. [CrossRef]

43. Pittas, A.G.; Dawson-Hughes, B.; Sheehan, P.; Ware, J.H.; Knowler, W.C.; Aroda, V.R.; Brodsky, L.; Ciglia, L.; Chatterjee, R.; Desouza, C.; et al. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N. Engl. J. Med. 2019, 381, 520–530. [CrossRef]

44. Saif-Elnasr, M.; Ibrahim, I.M.; Alkady, M.M. Role of Vitamin D on glycemic control and oxidative stress in type 2 diabetes mellitus. J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci. 2017, 22. [CrossRef]

45. Colak, E.; Majki´c-Singh, N.; Stankovi´c, S.; Sreckovi´c-Dimitrijevi´c, V.; Djordjevi´c, P.; Lali´c, K.; Lali´c, N. Parameters of antioxidative defense in type 2 diabetic patients with cardiovascular complications. Ann. Med. 2005, 37, 613–620. [CrossRef]

46. Blankenberg, S.; Rupprecht, H.J.; Bickel, C.; Torzewski, M.; Hafner, G.; Tiret, L.; Smieja, M.; Cambien, F.; Meyer, J.; Lackner, K. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. New Engl. J. Med. 2003, 349, 1605–1613. [CrossRef]

47. Espinola-Klein, C.; Rupprecht, H.J.; Bickel, C.; Schnabel, R.; Genth-Zotz, S.; Torzewski, M.; Lackner, K.; Munzel, T.; Blankenberg, S. Glutathione peroxide-1 activity, atherosclerotic burden, and cardiovascular prognosis. Am. J. Cardiol. 2007, 99, 808–812. [CrossRef]

48. Harijith, A.; Ebenezer, D.L.; Natarajan, V. Reactive oxygen species at the crossroads of inflammasome and inflammation. Front. Physiol. 2014, 5, 352. [CrossRef]

49. Dzik, K.; Skrobot, W.; Flis, D.J.; Karnia, M.; Libionka, W.; Kloc, W.; Kaczor, J.J. Vitamin D supplementation attenuates oxidative stress in paraspinal skeletal muscles in patients with low back pain. Eur. J. Appl. Physiol. 2018, 118, 143–151. [CrossRef]

50. Saedisomeolia, A.; Taheri, E.; Djalali, M.; Djazayeri, A.; Qorbani, M.; Rajab, A.; Larijani, B. Vitamin D status and its association with antioxidant profiles in diabetic patients: A cross-sectional study in Iran. Indian J. Med. Sci. 2013, 67, 29–37.

51. Baez-Duarte, B.G.; Zamora-Ginez, I.; Mendoza-Carrera, F.; Ruiz-Vivanco, G.; Torres-Rasgado, E.; Gonzalez-Mejia, M.E.; Garcia-Zapien, A.; Flores-Martinez, S.E.; Perez-Fuentes, R. Serum levels of glutathione peroxidase 3 in overweight and obese subjects from central Mexico. Arch. Med. Res. 2012, 43, 541–547. [CrossRef] [PubMed]

52. Al-Daghri, N.M.; Al-Saleh, Y.; Aljohani, N.; Alokail, M.; Al-Attas, O.; Alnaami, A.M.; Sabico, S.; Alsulaimani, M.; Al-Harbi, M.; Alfawaz, H.; et al. Vitamin D deficiency and cardiometabolic risks: A juxtaposition of Arab adolescents and adults. PLoS ONE 2015. [CrossRef] [PubMed]

53. Al-Daghri, N.M.; Alokail, M.S.; Manousoiu-Polou, A.; Heinson, A.; Al-Attas, O.; Al-Saleh, Y.; Sabico, S.; Yakout, S.; Woelk, C.H.; Chrousos, G.P.; et al. Sex-specific vitamin D effects on blood coagulation among overweight adults. Eur. J. Clin. Investig. 2016, 46, 1031–1040. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).